New hope for young adults battling leukemia: experimental treatment enters testing
NCT ID NCT05581030
Summary
This study is testing the safety of adding a new drug called calaspargase pegol to a standard chemotherapy regimen for young adults newly diagnosed with acute lymphoblastic leukemia. Researchers want to see if this combination is safe and can help patients achieve and maintain remission. The study will enroll a small group of participants to closely monitor their response and any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.